UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(MARK ONE)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2001
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
Commission File Number: 000-30347
--------------------------------
CURIS, INC.
(Exact Name of Registrant as Specified in Its Charter)
DELAWARE 04-3505116
(State or Other Jurisdiction (I.R.S. Employer Identification No.)
of Incorporation or Organization)
61 MOULTON STREET, CAMBRIDGE, MASSACHUSETTS 02138
(Address of Principal Executive Offices) (Zip Code)
Registrant's Telephone Number, Including Area Code: (617) 503-6500
-----------------------------------
Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
[x] Yes [ ] No
APPLICABLE ONLY TO CORPORATE ISSUERS:
As of November 9, 2001, there were 32,282,303 shares of the Registrant's Common
Stock, $0.01 par value per share, and there were 1,000 shares of the
Registrant's Series A Convertible Exchangeable Preferred Stock, $0.01 par value
per share, outstanding.
CURIS, INC. AND SUBSIDIARIES
QUARTERLY REPORT ON FORM 10-Q
INDEX
PART I. FINANCIAL INFORMATION Page Number
Item 1. Financial Statements (unaudited)
Condensed Consolidated Balance Sheets as of
September 30, 2001 and December 31, 2000 3
Consolidated Statements of Operations and
Comprehensive Loss for the Three Months
and Nine Months ended September 30, 2001
and 2000 4
Consolidated Statements of Cash Flows for
the Nine Months ended September 30, 2001
and 2000 5
Notes to Unaudited Condensed Consolidated
Financial Statements 6
Item 2. Management's Discussion and Analysis of
Financial Condition and Results of Operations 12
Item 3. Quantitative and Qualitative Disclosures
About Market Risk 21
PART II. OTHER INFORMATION
Item 2. Changes in Securities and Use of Proceeds 21
Item 6. Exhibits and Reports on Form 8-K 22
SIGNATURES
ITEM 1. FINANCIAL STATEMENTS
CURIS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
September 30, December 31 ,
2001 2000
-------------- ------------
ASSETS
- ------
CURRENT ASSETS:
Cash and cash equivalents $ 48,395,466 $ 52,414,312
Marketable securities 12,889,828 22,654,393
Marketable securities - restricted 613,924 729,905
Other current assets 2,163,461 1,278,873
----------------- ------------------
Total current assets 64,062,679 77,077,483
----------------- ------------------
PROPERTY, PLANT AND EQUIPMENT - net 10,900,146 7,866,591
----------------- ------------------
OTHER ASSETS:
Intangible assets, net (Note 4) 79,670,952 97,145,664
Other assets 5,243,751 592,252
----------------- ------------------
Total other assets 84,914,703 97,737,916
----------------- ------------------
$ 159,877,528 $ 182,681,990
================= ==================
LIABILITIES AND STOCKHOLDERS' EQUITY
- ------------------------------------
CURRENT LIABILITIES:
Debt and lease obligations, current portion $ 2,681,695 $ 1,971,609
Accounts payable 3,750,536 2,187,824
Accrued liabilities 6,560,664 5,553,641
Deferred revenue, current portion 626,555 -
----------------- ------------------
Total current liabilities 13,619,450 9,713,074
----------------- ------------------
DEBT AND LEASE OBLIGATIONS, net of current portion 6,655,094 4,155,150
DEFERRED REVENUE, net of current portion 11,518,978 -
COMMITMENTS (Note 4)
STOCKHOLDERS' EQUITY:
Preferred stock, $0.01 par value, 5,000,000 12,161,155 -
shares authorized, 1,000 and no shares
issued and outstanding at September 30, 2001
and December 31, 2000, respectively
Common stock, $0.01 par value, 125,000,000 322,814 313,836
shares authorized, 32,281,380 and 31,383,585
shares issued and outstanding at September 30,
2001 and December 31, 2000, respectively
Additional paid-in capital 664,624,878 662,339,492
Notes receivable (1,269,449) (1,204,596)
Deferred stock-based compensation (10,657,127) (22,893,619)
Accumulated deficit (537,701,487) (471,945,648)
Accumulated other comprehensive income 603,222 2,204,301
----------------- ------------------
Total stockholders' equity 128,084,006 168,813,766
------------------ ------------------
$ 159,877,528 $ 182,681,990
================= ==================
See accompanying notes to unaudited consolidated financial statements
3
CURIS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)
Three Months Ended Nine Months Ended
September 30, September 30,
----------------------------------- --------------------------------
2001 2000 2001 2000
--------------- ----------------- --------------- --------------
REVENUES:
Royalties, research and development
Revenues $ 287,915 $ 65,955 $ 739,718 $ 743,813
-------------- --------------- ------------- --------------
COSTS AND EXPENSES (A):
Research and development 6,901,611 6,056,255 22,903,482 10,072,461
General and administrative 2,456,488 4,040,568 7,711,170 6,642,813
Stock-based compensation 1,726,532 9,356,112 9,225,641 12,495,590
Amortization of intangible assets 5,827,392 8,529,302 17,474,712 8,647,473
Loss on disposition of fixed assets - 553,912 - 248,516
In-process research & development - 294,800,000 - 294,800,000
1999 reorganization - - - (38,391)
-------------- --------------- ------------- --------------
Total costs and expenses 16,912,023 323,336,149 57,315,005 332,868,462
-------------- --------------- ------------- --------------
Net loss from operations (16,624,108) (323,270,194) (56,575,287) (332,124,649)
-------------- --------------- ------------- --------------
Equity in loss from joint venture (12,697,406) - (12,697,406) -
Total other income, net 796,067 400,959 3,663,009 898,890
-------------- --------------- ------------- --------------
NET LOSS $(28,525,447) $(322,869,235) $(65,609,684) $(331,225,759)
Accretion of preferred stock dividend $ (146,155) $ - $ (146,155) $ -
-------------- --------------- ------------- --------------
Net loss applicable to common
stockholders $(28,671,602) $(322,869,235) $(65,755,839) $(331.225,759)
============== =============== ============= ==============
BASIC AND DILUTED NET LOSS PER COMMON
SHARE $ (0.89) $ (15.19) $ (2.08) $ (22.59)
============== =============== ============= ==============
WEIGHTED AVERAGE COMMON SHARES FOR
BASIC AND DILUTED NET LOSS
COMPUTATION 32,136,744 21,250,137 31,543,300 14,662,960
============== =============== ============= ==============
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
NET LOSS $(28,525,447) $(322,869,235) $(65,609,684) $(331,225,759)
============== =============== ============= ==============
UNREALIZED GAIN (LOSS) ON MARKETABLE
SECURITIES 8,712 (327,009) 81,868 4,921,987
ACCRETION OF PREFERRED STOCK DIVIDEND (146,155) - (146,155) -
UNREALIZED (LOSS) GAIN ON MARKETABLE
SECURITIES-RESTRICTED (402,318) 9,318 (115,981) (14,075)
-------------- --------------- ------------- --------------
COMPREHENSIVE LOSS $(29,065,208) $(323,186,926) $(65,789,952) $(326,317,847)
============== =============== ============= ==============
(A)The following summarizes the
departmental allocation of the
stock-based compensation charge:
Research and development $ 935,119 $ 5,726,801 $ 5,685,343 $ 5,726,801
General and administrative 791,413 3,629,311 3,540,298 6,768,789
-------------- --------------- ------------- --------------
Total stock-based
compensation $ 1,726,532 $ 9,356,112 $ 9,225,641 $ 12,495,590
============== =============== ============= ==============
See accompanying notes to unaudited consolidated financial statements
4
CURIS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
Nine-Month Periods Ended
September 30,
-----------------------------------
2001 2000
---------------- ---------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $(65,609,684) $(331,225,759)
---------------- ---------------
Adjustments to reconcile net loss to net cash used:
Depreciation and amortization 1,812,496 634,595
Stock-based compensation expense 9,225,641 12,495,590
Loss on disposal of assets - 248,516
Amortization of lease discount 18,467 28,734
Amortization of note discount 13,319 -
Reorganization expense adjustment - 39,141
Curis loss on acquired technology of joint venture 12,015,000 -
Issuance of common stock in lieu of cash for license fee 98,003 -
Non-cash interest on notes payable 10,831 12,782
Interest on notes receivable (64,853) -
Amortization of intangible assets 17,474,712 8,647,473
Write-off of in-process research and development - 294,800,000
Changes in assets and liabilities:
Other current assets (854,588) 455,940
Accounts payable and accrued liabilities 2,560,822 (385,058)
Deferred contract revenue 12,145,533 -
---------------- ---------------
Total adjustments 54,455,383 316,977,713
---------------- ---------------
Net cash used for operating activities (11,154,301) (14,248,046)
---------------- ---------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of marketable securities (16,106,659) (8,226,957)
Sale of marketable securities, net 24,386,126 26,040,734
Purchase of common and preferred shares in Curis Newco, Inc. (12,015,000) -
(Increase) decrease in other assets (4,681,499) 101,666
Expenditures for property, plant and equipment (1,888,399) (537,260)
Proceeds from sale of fixed assets - 675,000
Expenditures for patents - (563,882)
Cash received from acquisition of Ontogeny
and Reprogenesis, net of acquisition costs - 10,788,955
---------------- ---------------
Net cash (used in) provided by investing activities (10,305,431) 28,278,256
---------------- ---------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of common stock, net of issuance costs 4,630,643 4,208,860
Proceeds from exercise of warrants - 307,561
Issuance of convertible note payable 2,000,000 -
Proceeds from issuance of series A preferred shares 12,015,000 -
Repayment of notes payable (83,800) -
Repayments of obligations under capital leases (1,120,957) (672,121)
---------------- ---------------
Net cash provided by financing activities 17,440,886 3,844,300
---------------- ---------------
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (4,018,846) 17,874,510
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 52,414,312 2,751,069
---------------- ---------------
CASH AND CASH EQUIVALENTS, END OF PERIOD $ 48,395,466 $ 20,625,579
================ ===============
SUPPLEMENTAL DISCLOSURE OF NON-CASH $ 2,957,652 $ -
INVESTING AND FINANCING ACTIVITIES:
Property and equipment purchased under line of credit
================ ===============
Payment of notes payable by issuance of common stock $ 310,200 $ -
================ ===============
Issuance of notes receivable for exercise of stock options $ - $ 1,131,380
================ ===============
See accompanying notes to unaudited consolidated financial statements
5
CURIS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
1. Merger - On July 31, 2000 (the "Merger Date"), Creative BioMolecules, Inc., a
------
Delaware corporation ("Creative"), Ontogeny, Inc., a Delaware corporation
("Ontogeny"), and Reprogenesis, Inc., a Texas corporation ("Reprogenesis"),
merged (the "Merger") with and into Curis, Inc. (the "Company"), pursuant to
an Agreement and Plan of Merger dated as of February 14, 2000 (the "Merger
Agreement"). On July 31, 2000, the Company, as the surviving company of the
Merger, assumed the rights and obligations of Creative, Ontogeny and
Reprogenesis. Immediately after the Merger, the Company was owned
approximately 43% by the former stockholders of Creative, 38% by the former
stockholders of Ontogeny and 19% by the former stockholders of Reprogenesis.
Consequently, for accounting purposes, the Company is deemed to be the
successor to Creative, and the historical financial statements of Creative
have become the historical financial statements of the Company. The Merger
has been accounted for as a purchase of Ontogeny and Reprogenesis in
accordance with Accounting Principles Board (APB) Opinion No. 16, Accounting
for Business Combinations, and accordingly, Ontogeny's and Reprogenesis'
operating results prior to the Merger Date are not included in the
accompanying financial statements.
In accordance with APB No. 16, the purchase price for Ontogeny and
Reprogenesis has been allocated to the assets and liabilities of Ontogeny
and Reprogenesis based on their fair values. The aggregate purchase price
based on the fair market value of Creative common stock was $300,731,000 and
$149,000,000 for Ontogeny and Reprogenesis, respectively, including the value
of the outstanding options and warrants exchanged for options and warrants to
purchase the Company's common stock and the transaction costs related to the
Merger.
The purchase price of Ontogeny and Reprogenesis was allocated to the assets
acquired based upon an independent appraisal which used proven valuation
tools and techniques. Significant portions of the purchase price were
identified as intangible assets which included in-process research and
development ("IPR&D") of $294,800,000 and assembled workforce of $500,000.
The excess of the purchase price over the fair value of identified tangible
and intangible net assets of $105,477,000 has been allocated to goodwill.
Intangible assets are being amortized over their estimated useful lives of
four to five years. The fair value of the IPR&D relating to current in-
process research and development projects was recorded as an expense as of
the Merger Date.
Unaudited pro forma operating results for the three- and nine-month periods
ended September 30, 2000, assuming the Merger occurred at January 1, 2000 are
approximately as follows:
Three Months Ended Nine Months Ended
(Actual) (Pro forma) (Actual) (Pro forma)
September 30, September 30, September 30, September 30,
2001 2000 2001 2000
-----------------------------------------------------------------------------------------------------------
Revenues $ 288,000 $ 1,597,000 $ 740,000 $ 4,207,000
Net Loss $(28,525,000) $(25,859,000) $(65,610,000) $(64,621,101)
Net Loss per share $ (0.89) $ (1.00) $ (2.08) $ (2.49)
For purposes of these pro forma operating results, the IPR&D was assumed to
have been written off prior to the pro forma periods, so that the operating
results presented only include recurring costs.
2. Basis of Presentation - The accompanying consolidated financial statements of
---------------------
the Company have been prepared in accordance with accounting principles
generally accepted in the United States applicable to
6
interim periods. These statements, however, are condensed and do not include
all disclosures required by accounting principles generally accepted in the
United States for complete financial statements and should be read in
conjunction with the Company's Annual Report on Form 10-K for the year ended
December 31, 2000, as filed with the Securities and Exchange Commission on
March 30, 2001.
In the opinion of the Company, the unaudited financial statements contain all
adjustments (all of which were considered normal and recurring) necessary to
present fairly the Company's financial position at September 30, 2001 and the
results of operations and cash flows for the three- and nine-month periods
ended September 30, 2001 and 2000. The preparation of the Company's
consolidated financial statements in conformity with accounting principles
generally accepted in the United States requires management to make estimates
and assumptions that affect the reported amounts and disclosure of certain
assets and liabilities at the balance sheet date. Such estimates include the
carrying value of property and equipment and intangible assets and the value
of certain liabilities. Actual results may differ from such estimates.
These interim results are not necessarily indicative of results for a full
year and are subject to year-end adjustments and an independent audit.
3. Intangible Assets - Intangible assets consisted of approximately the
-----------------
following as of September 30, 2001 and December 31, 2000:
September 30, December 31,
2001 2000
------------- -------------
Goodwill $105,477,000 $105,477,000
Patents 1,297,000 1,297,000
Assembled workforce 500,000 500,000
------------- ------------
107,274,000 107,274,000
Less: accumulated amortization (27,603,000) (10,128,000)
------------- ------------
$ 79,671,000 $ 97,146,000
============ ============
Goodwill totaling $105,477,000 and assembled workforce of $500,000 are being
amortized over their estimated useful lives of four to five years.
Accumulated amortization as of September 30, 2001 was $26,977,000 and
$117,000 for goodwill and assembled workforce, respectively. The Company has
capitalized certain costs associated with the successful filing of patent
applications and has included them as a component of other assets in the
accompanying consolidated balance sheet. Patent costs of $1,297,000 are
being amortized over their estimated useful lives, not to exceed 17 years.
Accumulated amortization relating to patent costs was $509,000 as of
September 30, 2001.
4. On August 3, 2001, the Company entered into a loan agreement with Doros
Platika, Chairman of the Company, totaling $500,000. The loan is full
recourse and bears interest at an annual rate of 8.0%. All principal and
interest is due in full on December 31, 2001, unless amended by the Company
and Dr. Platika. Dr. Platika's obligations under the loan are secured by a
pledge of all of Dr. Platika's shares of the Company's common stock. In
addition, during the term of the loan agreement, Dr. Platika has agreed not
to transfer any rights he has to acquire the Company's common stock.
7
5. Long-Term Debt, Capital Lease Obligations and Operating Leases -
--------------------------------------------------------------
(i) Long-term debt and capital lease obligations consisted of approximately
the following at September 30, 2001 and December 31, 2000:
September 30, December 31,
2001 2000
-----------------------------------
Notes payable to a financing agency $ 4,616,000 $ 1,946,000
purchases for fixed asset
Notes payable to Genetics Institute - 394,000
Convertible subordinated notes 1,784,000 -
payable to Becton Dickinson, net of
$253,000 discount at September 30, 2001
Obligations under capital leases, net of
$54,000 discount at September 30, 2001 2,937,000 3,787,000
-----------------------------------
9,337,000 6,127,000
Less current portion (2,682,000) (1,972,000)
-----------------------------------
Total long-term debt and capital
lease obligations $ 6,655,000 $ 4,155,000
===================================
On May 31, 2001 the Company issued 60,000 shares of common stock valued at
$310,000 and paid cash totaling $195,000 to repay in full all notes payable
due to Genetics Institute for technology purchases, including accrued
interest of $111,000.
On June 27, 2001, the Company received $2,000,000 from Becton Dickinson under
a convertible subordinated note payable in connection with the exercise of an
option to negotiate a collaboration agreement. The note is repayable, at the
option of the Company, in either cash or upon issuance of the Company's
common stock at any time up to its maturity date of June 26, 2006. The note
bears interest at 7%, which is below the fair market interest rate which the
Company estimates to be 11%. The difference between the market interest rate
of 11% and the coupon interest rate of 7% is being accounted for as a
discount and is being amortized as additional interest expense over the
remaining term of the note.
(ii) Future minimum operating lease payments for the respective periods
ended December 31 are approximately as follows:
Operating Leases
- ----------------------------- -------------------
Q4 2001 $ 464,000
2002 1,956,000
2003 2,020,000
2004 2,004,000
2005 2,002,000
Thereafter 2,659,000
---------------
Total minimum lease payments $11,105,000
===============
6. License Agreement - Effective January 5, 2001, the Company entered into a
-----------------
license and collaboration agreement with Aegera Therapeutics Inc.
("Aegera") granting the Company an exclusive worldwide license to Aegera's
skin-derived, adult stem cell technologies. The agreement also provides
for a three-year research collaboration in which the Company will fund 6
full-time equivalent researchers per year at Aegera dedicated to the
agreement. In consideration for the technology license, the Company paid a
$100,000 up-front license fee, purchased 125,000 shares of Aegera common
stock for
8
a total cost of $250,000 and issued to Aegera 10,667 shares of the
Company's common stock, which had a market value of approximately $98,000,
during the first quarter of 2001. The Company recorded the $100,000 payment
and fair value of the Company's common stock issued to Aegera as an expense
in the accompanying statement of operations. The estimated fair value of
125,000 shares of Aegera common stock purchased has been recorded as an
other asset in the accompanying balance sheet. In addition, under the terms
of the agreement, the Company will likely be required to make various
milestone and royalty related payments.
7. Micromet Collaboration - On June 29, 2001, the Company entered into a
----------------------
purchase and sale agreement with Micromet, AG ("Micromet"), a German
corporation, pursuant to which the Company assigned its single-chain-
polypeptide technology to Micromet in exchange for $8,000,000 in cash,
3,003 shares of Micromet common stock valued at approximately $686,000 and
a convertible promissory note ("Note") of EUR 4,068,348 (approximately
$3,732,000 at September 30, 2001). The convertible promissory note bears
interest at 7% and is due the earlier of (i) the closing date for an
initial public offering of Micromet's shares or (ii) June 30, 2005. The
Company has recorded a long-term receivable of approximately $64,000
relating to accrued interest on the Note. Upon reaching maturity, the
Company has the option to receive either cash or shares of Micromet common
stock.
In addition, on June 29, 2001, the Company entered into a letter of intent
with Micromet pursuant to which the parties agreed to enter into a target
research and license agreement and a product development agreement. It is
intended that these agreements will provide the Company with royalties on
Micromet's product revenues, if any, arising out of the assigned
technology, joint ownership of future product discoveries, if any, arising
out of the collaboration, and access by Curis to Micromet's proprietary
single cell analysis of gene expression technology. In addition, it is
intended that the product development agreement will require the Company to
jointly fund research for potential targets through the proof of principle
stage. The Company will also have the right, but not the obligation, to
jointly or solely fund the development of targets from the proof of
principle stage through the completion of Phase I Clinical Trials. Lastly,
the Company will be obligated to pay milestones to Micromet upon the
attainment of certain development goals. As of September 30, 2001, the
Company had not entered into the target research and license agreement and
product development agreement.
The convertible promissory note and estimated value of the Micromet common
stock have been recorded as a component of other assets in the accompanying
balance sheet due to the long-term nature of the underlying instruments.
The Company will recognize as revenue the value of all consideration
received from Micromet under the purchase and sale agreement over the
Company's estimated performance period under the product development
agreement. No revenue has been recognized under this arrangement as of
September 30, 2001. Accordingly, the Company has recorded short-term and
long-term deferred revenue of approximately $627,000 and $11,519,000,
respectively, in the accompanying Balance Sheet at September 30, 2001.
8. Curis Newco, Ltd. - On July 18, 2001, the Company and Elan International
----------------
Services ("EIS") formed Curis Newco, Ltd. ("Newco"), an entity that is
committed to the research and development of molecules that stimulate the
hedgehog (Hh) signaling pathway. This pathway had previously been shown to
play a role in the development of the central and peripheral nervous
systems. At the time Newco was formed, EIS purchased 546,448 shares of the
Company's common stock for $4,000,000, or $7.32 per share, and received a
warrant to purchase up to 50,000 shares of the Company's common stock at
$10.46 per share. The warrant is exercisable for five years. Also, EIS
purchased 1,000 shares of the Company's newly created Series A convertible
exchangeable preferred stock ("Series A Preferred Stock") for proceeds of
$12,015,000. The Series A Preferred Stock is, at EIS's option, convertible
into the Company's common stock at $14.12 per share or exchangeable for
non-voting preference shares of Newco ("Newco Preference Shares"),
originally issued to the Company and representing 30.1% of the aggregate
outstanding shares of Newco ("Aggregate Newco Shares"). The Company used
the $12,015,000 in proceeds of the Series A Preferred Stock sale to
purchase 80.1% of the Aggregate Newco Shares. This purchase consisted of
100% of the voting common shares of
9
Newco ("Newco Common Shares") and 60.2% of the Newco Preference Shares,
which represent 50% and 30.1%, respectively, of the Aggregate Newco Shares.
In addition, EIS contributed $2,985,000 to purchase 39.8% of the Newco
Preference Shares, which represent 19.9% of the Aggregate Newco Shares.
Newco used the aggregate proceeds to pay $15,000,000 to Neuralab Limited,
an affiliate of EIS, for a non-exclusive license giving Newco rights to use
an important animal model, a mouse strain that develops many of the
features of human neurodegenerative diseases. Upon completing this
transaction, the cost of this license was expensed as a research and
development cost of Newco as the technology acquired had not yet reached
technological feasibility and there was no future alternative use for the
technology. The Company's share of this expense was approximately
$12,015,000 and is included in Equity in Loss from Joint Venture in the
accompanying Statement of Operations for the three-and nine-months ended
September 30, 2001.
Newco was formed by issuing Newco Common Shares and Newco Preference Shares
valued at $15,000,000 to the Company and EIS. The Company owns 100% of the
outstanding Newco Common Shares, which represents 100% of the outstanding
voting Newco shares. The Newco Preference shares are non-voting and are
convertible, at the option of the holder thereof, into voting Newco Common
Shares at any time after July 18, 2003. While EIS currently does not own
any Newco Common Shares and is unable to convert any of its Newco
Preference Shares into Newco Common Shares until July 18, 2003, it has
retained significant minority investor rights that the Company considers to
be "participating rights" as defined in Emerging Issues Task Force (EITF)
Issue 96-16 Investors' Accounting for an Investee When the Investor Has a
Majority of the Voting Interest but the Minority Shareholder Has Certain
Approval or Veto Rights. EIS's participating rights prevent the Company
from exercising sole control over Newco with respect to certain enumerated
actions related to the technology licensed from Neuralab Limited.
Accordingly, the Company will not consolidate the financial statements of
Newco but instead will account for its investment in Newco under the equity
method of accounting.
The Company may provide additional funding to Newco as needed in relation
to its ownership interest in Newco. On July 18, 2001, the Company entered
into an $8,010,000 convertible promissory note agreement (the "Note
Agreement") with Elan Pharma International Limited ("EPIL"). The Note
Agreement bears interest at 8% per annum through July 18, 2005 and 6% per
annum thereafter, compounded and payable semi-annually. Under the terms of
the Note Agreement, EPIL has the option to convert all or any portion of
the outstanding principal amount into the Company's common stock under
certain circumstances at any time after July 18, 2003, at a per share price
of $8.63, subject to adjustment under certain circumstances, as defined.
The borrowings under the Note Agreement are restricted to the Company's
development funding of Newco. As of September 30, 2001, there were no
borrowings outstanding under the Note Agreement.
The Company incurred research expenses of approximately $852,000 on behalf
of Newco during the period of July 18, 2001 through September 30, 2001. The
Company's share of Newco expenses for the three-month period ended
September 30, 2001 was approximately $682,000 and is included in Equity in
loss from joint venture in the Company's Statement of Operations. The
Company also recorded a net receivable from Newco at September 30, 2001 of
approximately $170,000. This receivable represents EIS's 19.9% share of
expenses paid for by Curis on behalf of Newco.
The Company recorded a charge to retained earnings for the accretion of the
6% Series A preferred stock dividend of approximately $146,000. Such
amounts are included in the net loss applicable to common shareholders in
both the three-and nine-months ended September 30, 2001.
9. New Accounting Standards - In June 1998, the Financial Accounting
------------------------
Standards Board (FASB) released SFAS No. 133, Accounting for Derivative
Instruments and Hedging Activities. SFAS No. 133 establishes standards for
reporting and accounting for derivative instruments, including derivative
instruments embedded in other contracts, and for hedging activities. It
requires an entity to recognize all derivatives as either assets or
liabilities in its balance sheet and measure those instruments at fair
value. Pursuant to SFAS No. 137, Accounting for Derivative Instruments and
Hedging Activities -
10
Deferral of the Effective Date of FASB Statement No. 133, SFAS No.133 is
effective for all quarters of fiscal years beginning after June 15, 2000.
The adoption of SFAS No. 133 in the first quarter of fiscal 2001 did not
have any impact on the Company's reported consolidated financial
statements.
On June 30, 2001, the FASB issued SFAS No. 141, Accounting for Business
Combinations and SFAS No. 142, Accounting for Goodwill and Other Intangible
Assets. SFAS No. 141 requires that all business combinations initiated
after June 30, 2001 be accounted for under the purchase method. Upon
adoption of SFAS 142, goodwill and assembled workforce will no longer be
subject to amortization over its estimated useful life. Rather, goodwill
will be subject to at least an annual assessment of impairment by applying
a fair-value based test. Upon adoption of SFAS 142 on January 1, 2002, the
Company will cease amortization of its existing goodwill and assembled
workforce thereby reducing its operating expenses by approximately
$11,500,000 annually. The Company has not yet assessed the impairment, if
any, that would be recognized utilizing a fair-value based goodwill
impairment test.
11
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
General
Curis, Inc. (the "Company"), incorporated on February 14, 2000 and formed to
effect the merger discussed below, is developing products that restore health
through regenerative therapeutics. the Company utilizes technologies and
insights gained through the study of developmental biology to facilitate the
discovery and development of new approaches to repair and regeneration of
tissues and organs damaged by disease and/or trauma. Through these discoveries,
the Company has developed a pipeline of promising new therapies for the
treatment of major diseases, including neurological disorders, diabetes,
oncology, cardiovascular and renal disease.
The Curis technology platform and product development pipeline is based on
developmental biology, signaling pathways, adult stem cells and cell-based
therapies. The Curis research program is conducted both internally and through
alliances, partnerships and joint ventures with companies and organizations
including Aegera Therapeutics and McGill University, Montreal, Canada; Micromet
AG, Munich, Germany ("Micromet"); and Elan Corporation, Dublin, Ireland
("Elan").
On July 31, 2000 (the "Merger Date"), Creative BioMolecules, Inc., a Delaware
corporation ("Creative"), Ontogeny, Inc., a Delaware corporation ("Ontogeny"),
and Reprogenesis, Inc., a Texas corporation ("Reprogenesis"), merged (the
"Merger") with and into the Company, pursuant to an Agreement and Plan of Merger
dated as of February 14, 2000 (the "Merger Agreement"). On the Merger Date, the
Company, as the surviving company of the Merger, assumed the rights and
obligations of Creative, Ontogeny and Reprogenesis. Immediately after the
Merger, the Company was owned approximately 43% by the former stockholders of
Creative, 38% by the former stockholders of Ontogeny and 19% by the former
stockholders of Reprogenesis. Consequently, for accounting purposes, the Company
is deemed to be the successor to Creative, and the historical financial
statements of Creative have become the historical financial statements of the
Company. The Merger has been accounted for as a purchase of Ontogeny and
Reprogenesis in accordance with Accounting Principles Board (APB) Opinion No.
16, Accounting for Business Combinations, and accordingly, Ontogeny's and
Reprogenesis' operating results prior to the Merger Date are not included in the
accompanying financial statements.
In accordance with APB No. 16, the purchase price for Ontogeny and Reprogenesis
has been allocated to the assets and liabilities of Ontogeny and Reprogenesis
based on their fair values. The purchase price, which was based on the fair
market value of Creative common stock as of the Merger Date, consisted of
$300,731,000 and $149,000,000 for Ontogeny and Reprogenesis, respectively. The
purchase price paid for each entity includes the value of the outstanding
options and warrants exchanged for options and warrants to purchase the
Company's common stock and the transaction costs related to the Merger.
The purchase price of Ontogeny and Reprogenesis was allocated to the assets
acquired based upon an independent appraisal which used proven valuation tools
and techniques. Significant portions of the purchase price were identified as
intangible assets which included in-process research and development ("IPR&D")
of $294,800,000 and assembled workforce of $500,000. The excess of the purchase
price over the fair value of identified tangible and intangible net assets of
$105,477,000 has been allocated to goodwill. Intangible assets are being
amortized over their estimated useful lives of 4 to 5 years. The fair value of
the IPR&D relating to current in-process research and development projects was
recorded as an expense as of the Merger Date.
Unaudited pro forma operating results for the three- and nine-month periods
ended September 30, 2000, which assume the Merger occurred at January 1, 2000,
are approximately as follows:
12
Three-Months Ended Nine-Months Ended
(Actual) (Pro forma) (Actual) (Pro forma)
September 30, September 30, September 30, September 30,
2001 2000 2001 2000
-----------------------------------------------------------------------------------------------------------
Revenues $ 288,000 $ 1,597,000 $ 740,000 $ 4,207,000
Net Loss $(28,525,000) $(25,859,000) $(65,610,000) $(64,621,101)
Net Loss per share $ (0.89) $ (1.00) $ (2.08) $ (2.49)
For purposes of these pro forma operating results, the IPR&D was assumed to have
been written off prior to the pro forma periods, so that the operating results
presented only include recurring costs.
Operating results for the three- and nine-month periods ended September 30, 2001
include the operating expenses of the Company. Operating expenses for the
three- and nine-month periods ended September 30, 2000 include the operating
expenses of Creative only through the Merger Date and of the combined companies
from the Merger Date through the remainder of the respective periods. Expenses
for Ontogeny or Reprogenesis are not included through that date. Accordingly,
comparisons of operating results between the 2001 and the 2000 periods may not
prove to be meaningful.
RESULTS OF OPERATIONS
QUARTERS ENDED SEPTEMBER 30, 2001 AND SEPTEMBER 30, 2000
Revenues
Total revenues increased to $288,000 for the three-month period ended September
30, 2001 from $66,000 for the three-month period ended September 30, 2000.
Revenues for the three-month period ended September 30, 2001 include $239,000 in
revenues received under two National Institute of Standards and Technology
("NIST") grants and $49,000 in royalty revenues received from Stryker
Corporation ("Stryker"). Revenues for the three-month period ended September 30,
2000 include $56,000 in revenues received under a NIST grant and $10,000 in
license revenues received from Stryker.
OPERATING EXPENSES
Research and development expenses increased 14% to $6,902,000 for the three-
month period ended September 30, 2001 from $6,056,000 for the three-month period
ended September 30, 2000. The increase was primarily due to the impact of
combining the three companies involved in the Merger offset in part by one-time
charges incurred in connection with the Merger during the three-month period
ended September 30, 2000 including severance paid to former officers of Creative
of $656,000 and severance paid to seven other employees totaling $251,000.
Research and development expenses for the three-month period ended September 30,
2001 include the costs of 106 employees involved in research and development
totaling $2,052,000, outside services including clinical trials, medicinal
chemistry, consulting and sponsored research collaborations of $1,868,000, lab
and clinical trial manufacturing supplies of $955,000, occupancy and
depreciation charges of $934,000, and legal fees associated with the Company's
intellectual property of $808,000.
General and administrative expenses decreased 39% to $2,456,000 for the three-
month period ended September 30, 2001 from $4,041,000 for the three-month period
ended September 30, 2000. The decrease was primarily due to one-time charges
incurred in connection with the Merger during the three-month period ended
September 30, 2000 including severance paid former officers of Creative of
$926,000 and severance paid to the termination of eight other employees totaling
$122,000. General and administrative expenses for the three-month period ended
September 30, 2001 include the costs of 34 employees totaling $970,000,
professional service fees and other outside services including legal costs and
consultants of $855,000 and occupancy and depreciation charges of $475,000.
13
Stock-based compensation decreased to $1,727,000 for the three-month period
ended September 30, 2001 from $9,356,112 for the three-month period ended
September 30, 2000. The decrease was primarily due to $6,624,000 of
amortization expense related to deferred compensation resulting from the Merger
which is being amortized over the vesting period of the underlying options
through August 1, 2001 recorded in the three months ended September 30, 2000
compared to $776,000 during the three-month period ended September 30, 2001.
Also, 57,094 shares of restricted common stock granted to a former Reprogenesis
executive officer became fully vested as unrestricted common stock of the
Company upon the Merger. Total expense included in the three-month period ended
September 30, 2000 related to these shares was $1,623,000. Finally, on August
18, 2000, the Company issued 3,473,006 options to its employees with an exercise
price below market value resulting in deferred compensation of $18,233,000 which
is being amortized over the four-year vesting period of the shares beginning on
August 1, 2000. The total expense included in the three-month periods ended
September 30, 2001 and September 30, 2000 related to these options was $951,000
and $762,000, respectively.
Amortization of intangible assets was $5,827,000 for three-month period ended
September 30, 2001 as compared to $8,529,000 for the three-month period ended
September 30, 2000. The decrease was primarily due to an impairment charge
recorded in the three-month period ended September 30, 2000 of $4,611,000 to
reduce the carrying value of capitalized patents determined not to be beneficial
or to be utilized in future operations and which have no alternative future use
offset in part by increased amortization of goodwill and assembled workforce
incurred as a result of the Merger totaling $5,803,000 for the three-month
period ended September 30, 2001 compared to $3,880,000 for the three-month
periods ended September 30, 2000.
A fixed asset disposition charge of $554,000 was incurred during the three-
months ended September 30, 2000 for the book value of equipment disposed of as a
result of the Merger.
A charge of $294,800,000 was incurred on the Merger Date resulting from portions
of the purchase price of Ontogeny and Reprogenesis that were identified as
IPR&D. As described previously, the purchase price of Ontogeny and Reprogenesis
has been allocated to the assets acquired, including IPR&D, based upon an
independent appraisal which used proven valuation tools and techniques.
EQUITY IN LOSS FROM JOINT VENTURE
During the three-month period ended September 30, 2001, the Company incurred an
initial charge of $12,015,000 in conjunction with the Elan Joint Venture ("Elan
JV") as a result of the write off of technology acquired in July 2001. The
Company financed this loss with proceeds totaling $12,015,000 received from the
sale of 1,000 shares of its Series A Convertible Exchangeable Preferred Stock to
an affiliate of Elan. The Company expects to finance its share of the
development funding of the Elan JV through July 18, 2003 with draw downs under
an $8,010,000 convertible promissory note entered into between the Company and
an affiliate of Elan. The Company's portion of the Elan JV operating expenses
for the three-month period ended September 30, 2001 was $682,000.
OTHER INCOME, NET
Interest and other income for the three-month period ended September 30, 2001
was $991,000 compared to approximately $581,000 for the same period in 2000, an
increase of $410,000 or 71%. The increase in interest income for the three-
month period resulted primarily from a higher available investment balance as
compared to the prior year as a result of the Merger and net proceeds of
$45,548,000 received from a private placement of equity securities completed in
December 2000.
Interest expense for the three-month period ended September 30, 2001 was
$195,000 compared to $180,000 for the same period in 2000, an increase of
$15,000 or 8%. The increase in interest expense resulted primarily from the
consolidation into the Company of the outstanding lease obligations of the
Ontogeny and Reprogenesis at the time of the merger and a line of credit
received in December 2000 for the purchase of equipment and leasehold
improvements.
14
ACCRETION OF PREFERRED STOCK DIVIDEND
The Company recorded a charge to retained earnings for the accretion of the 6%
Series A preferred stock dividend of approximately $146,000. Such amounts are
included in the net loss applicable to common shareholders in the three-months
ended September 30, 2001.
NET LOSS APPLICABLE TO COMMON STOCKHOLDERS
As a result of the foregoing, the Company incurred a net loss of $28,672,000 and
for the three-month period ended September 30, 2001 compared to a net loss of
$322,869,000 for the three-month period ended September 30, 2000.
NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2001 AND SEPTEMBER 30, 2000
REVENUES
Total revenues decreased to $740,000 for the nine-month period ended September
30, 2001 from $744,000 for the nine-month period ended September 30, 2000.
Revenues for the nine-month period ended September 30, 2001 include $661,000 in
revenues received under two NIST grants and $79,000 in royalty revenues received
from Stryker. Revenues for the nine-month period ended September 30, 2000
include $56,000 in revenues received under a NIST grants and $688,000 in license
revenues received from Stryker.
OPERATING EXPENSES
Research and development expenses increased 127% to $22,903,000 for the nine-
month period ended September 30, 2001 from $10,072,000 for the nine-month period
ended September 30, 2000. The increase was primarily due to the impact of
combining the three companies involved in the Merger offset in part by one-time
charges incurred in connection with the Merger during the nine-month period
ended September 30, 2000 including severance paid to former officers of
Creative of $656,000 and severance paid to seven other employees totaling
$251,000. Research and development expenses for the nine-month period ended
September 30, 2001 include the costs of 114 employees involved in research and
development totaling $6,658,000, outside services including clinical trials,
medicinal chemistry, consultants and sponsored research collaborations of
$7,035,000, occupancy and depreciation charges of $3,226,000, lab and clinical
trial manufacturing supplies of $2,842,000 and legal fees associated with the
Company's intellectual property of $1,893,000.
General and administrative expenses increased 16% to $7,711,000 for the nine-
month period ended September 30, 2001 from $6,643,000 for the nine-month period
ended September 30, 2000. The increase was primarily due to the impact of the
Merger offset in part by one-time charges incurred in connection with the Merger
during the nine-month period ended September 30, 2000 including severance paid
to former officers of Creative of $926,000 and severance paid to the termination
of eight other employees totaling $122,000. General and administrative expenses
for the nine-month period ended September 30, 2001 include the costs of 34
employees totaling $2,825,000, professional service fees including legal costs
and consultants of $2,466,000 and occupancy and depreciation charges of
$1,251,000.
Stock-based compensation decreased to $9,226,000 for the nine-month period ended
September 30, 2001 from $12,496,000 for the nine-month period ended September
30, 2000. The decrease was primarily due to a one-time non-cash charge of
$3,139,000 was recorded on February 8, 2000 related to the acceleration of
certain stock options and the extension of the exercise period for options held
by Creative's executive officers and outside directors. Additionally, a one-time
non-cash charge of $3,139,000 was recorded on February 8, 2000 related to the
acceleration of certain stock options and the extension of the exercise period
for options held by Creative's executive officers and outside directors. Also,
57,094 shares of restricted common stock granted to a former Reprogenesis
executive officer became fully vested as unrestricted common stock of the
Company upon the Merger. Total expense included in the three-month period ended
September 30, 2000 related to these shares was $1,623,000. Amortization expense
related to prepaid compensation resulting from the Merger which is being
amortized over the vesting period of the underlying options through August 1,
2001 was $6,220,000 in the nine months ended September 30, 2001 compared
$6,623,000 during the nine-month period
15
ended September 30, 2000. Finally, on August 18, 2000, the Company issued
3,473,006 options to its employees with an exercise price below market value
resulting in deferred compensation of $18,233,000 which is being amortized over
the four-year vesting period of the shares beginning on August 1, 2000. The
total expense included in the nine-month periods ended September 30, 2001 and
September 30, 2000 related to these options was $951,000 and $762,000,
respectively.
Amortization of intangible assets was $17,475,000 for nine-month period ended
September 30, 2001 as compared to $8,647,000 for the nine-month period ended
September 30, 2000. The increase was primarily due to increased amortization of
goodwill and assembled workforce incurred as a result of the Merger totaling
$17,410,000 for the nine-month period ended September 30, 2001 compared to
$3,880,000 for the nine-month periods ended September 30, 2000 offset in part by
an impairment charge recorded in the three-month period ended September 30, 2000
of $4,611,000 to reduce the carrying value of capitalized patents determined not
to be beneficial or to be utilized in future operations and which have no
alternative future use.
EQUITY IN LOSS FROM JOINT VENTURE
During the nine-month period ended September 30, 2001, the Company incurred an
initial charge of $12,015,000 in conjunction with the Elan JV as a result of
the write off of technology acquired in July 2001. The Company financed this
loss with proceeds totaling $12,015,000 received from the sale of 1,000
preferred shares to an affiliate of Elan. The Company expects to finance its
share of the development funding of the Elan JV through July 18, 2003 with draw
downs under an $8,010,000 convertible promissory note entered into between the
Company and an affiliate of Elan. The Company's portion of the Elan JV operating
expenses for the nine-month period ended September 30, 2001 was $682,000.
OTHER INCOME, NET
For the nine-month period ended September 30, 2001, interest and other income
was $4,222,000 compared to $1,164,000 for the nine-month period ended September
30, 2000, an increase of $3,058,000 or 263%. The increase in interest income
for the nine-month period resulted primarily from a $1,466,000 gain on the sale
of marketable securities in the nine-month period ended September 30, 2001.
Additionally, the Company had a higher average available investment balance as
compared to the prior year as a result of the Merger and net proceeds of
$45,548,000 received from a private placement of equity securities completed in
December 2000.
For the nine-month period ended September 30, 2001, interest expense was
$559,000 compared to $265,000 for the nine-month period ended September 30,
2000, an increase of $294,000 or 111%. The increase in interest expense
resulted primarily from the consolidation into the Company of the outstanding
lease obligations of Ontogeny and Reprogenesis at the time of the merger and a
line of credit received in December 2000 for the purchase of equipment and
leasehold improvements.
ACCRETION OF PREFERRED STOCK DIVIDEND
The Company recorded a charge to retained earnings for the accretion of the 6%
Series A preferred stock dividend of approximately $146,000. Such amounts are
included in the net loss applicable to common shareholders in the nine-months
ended September 30, 2001.
NET LOSS APPLICABLE TO COMMON STOCKHOLDERS
As a result of the foregoing, the Company incurred a net loss of $65,756,000 and
for the nine-month period ended September 30, 2001 compared to a net loss of
$331,226,000 for the nine-month period ended September 30, 2000.
16
LIQUIDITY AND CAPITAL RESOURCES
At September 30, 2001, the Company's principal sources of liquidity consisted of
cash, cash equivalents and marketable securities of $61,899,000. The Company
has financed its operations primarily through the sale of its equity securities,
consideration received under agreements with collaborative partners,
manufacturing contracts and the sale by Creative of certain of its OP-1
manufacturing rights and facilities to Stryker. Net cash used in operating
activities was $11,154,000 for the nine-month period ended September 30, 2001
compared to $14,248,000 for the nine-month period ended September 30, 2000. The
decrease was primarily due to one-time costs associated with the consolidation
of the three companies in the Merger incurred during the nine-month period ended
September 30, 2000. The Company increased its investment in property, plant and
equipment to $18,739,000 at September 30, 2001 from $13,893,000 at December 31,
2000. The increase resulted primarily from leasehold improvements and equipment
purchases incurred to upgrade the Company's research and development facilities.
The Company plans to spend approximately $1,500,000 during the remainder of 2001
on leasehold improvements and equipment purchases to upgrade its research and
development facilities.
On December 27, 2000, the Company entered into a term loan agreement with Fleet
National Bank (the "Bank") under which it is able to borrow up to $5,000,000 to
finance fixed asset purchases. Advances under this facility are to be repaid
over a 48-month period beginning on March 31, 2002. Interest on the advances is
at the Bank's LIBOR rate plus two and one-half basis points (4.66% as of
September 30, 2001). Advances under the facility are collateralized by all
capital equipment purchased with the funds under this facility. At
September 30, 2001, outstanding borrowings under this agreement totaled
$4,052,000.
On June 27, 2001, the Company entered into a purchase and sale agreement with
Micromet, AG ("Micromet"), a German corporation, pursuant to which the Company
assigned its single-chain-polypeptide technology to Micromet in exchange for
$8,000,000 in cash received on July 2, 2001, 3,003 shares of Micromet common
stock valued at approximately $686,000 and a convertible promissory note
("Note") of EUR 4,068,348 (approximately $3,732,000 at September 30, 2001).
In addition, on June 29, 2001, the Company entered into a letter of intent with
Micromet pursuant to which the parties agreed to enter into a target research
and license agreement and a product development agreement, as further described
in Note 7 to the financial statements. It is intended that the product
development agreement will require the Company to jointly fund research for
potential targets through the proof of principle stage. The Company will also
have the right, but not the obligation, to jointly or solely fund the
development of targets from the proof of principle stage through the completion
of Phase I Clinical Trials. Lastly, the Company will be obligated to pay
milestones to Micromet upon the attainment of certain development goals. As of
September 30, 2001, the Company has not entered into the target research and
license agreement and product development agreement.
On July 18, 2001, the Company and Elan International Services ("EIS") formed
Curis Newco, Ltd. ("Newco"), an entity that is committed to the research and
development of molecules that stimulate the hedgehog (Hh) signaling pathway,
this joint venture is further described in Note 8 of the financial statements.
As part of the joint venture arrangement, the Company entered into an $8,010,000
convertible promissory note agreement (the "Note Agreement") with Elan Pharma
International Limited ("EPIL"). The Note Agreement bears interest at 8% per
annum through July 18, 2005 and 6% per annum thereafter, compounded and payable
semi-annually. The borrowings under the Note Agreement are restricted to the
Company's development funding of Newco. As of September 30, 2001, there were no
borrowings outstanding under the Note Agreement. On October 5, 2000, the Company
announced the receipt of its second $2,000,000 grant from NIST to support the
development of a new class of biomaterials designed to enable surgical
procedures that augment, repair or regenerate lost structural tissue or
physiological function. The grant period is from January 1, 2001 to December
31, 2003. Previously, Reprogenesis had been awarded a $2,000,000 grant from
NIST to support the development of its cardiovascular products, Vascugel and
Vascuject. The grant period for the NIST grant made to Reprogenesis is from
November 1, 1999 to October 31, 2002.
On June 27, 2001, the Company received $2,000,000 from Becton Dickinson under a
convertible sub ordinated note payable in connection with the exercise by Becton
Dickinson of an option to negotiate a
17
collaboration agreement. The note is repayable at any time up to its maturity
date of June 26, 2006 by the Company, at its discretion, in either cash or upon
issuance to Becton Dickinson of shares of the Company's common stock. The note
bears interest at 7%.
As of September 30, 2001, the Company held 53,571 shares of common stock of
Exelixis, Inc. ("Exilixis") with a fair market value as of that date of
approximately $614,000, included in the Company's balance sheet as of September
30, 2001 under the category "Marketable securities - restricted." The sale of
these shares by the Company is restricted under an agreement between the Company
and Exelixis, which restricts their sale until the one-year holding period has
been satisfied on March 13, 2002. The value of these shares could fluctuate
based on the price of Exelixis common stock and market conditions.
The Company anticipates that existing capital resources and amounts to be
received pursuant to the Elan joint venture should enable it to maintain current
and planned operations into the second quarter of 2003. Beyond the second
quarter of 2003, the Company expects to incur substantial additional research
and development and other costs, including costs related to preclinical studies
and clinical trials. The Company's ability to continue funding planned
operations is dependent upon its ability to generate sufficient cash flows from
its royalty arrangements with Stryker, from its other collaborative arrangements
and from additional funds through equity or debt financings, or from other
sources of financing, as may be required. With respect to the Stryker royalty
arrangements, as with the Company's other collaborative arrangements, the
Company's ability to generate sufficient cash flows depends on a number of
factors including the ability to obtain regulatory approval to market and
commercialize products to treat additional indications in major commercial
markets. The Company is seeking additional collaborative arrangements and also
expect to raise funds through one or more financing transactions, if conditions
permit. Over the longer term, because of the Company's significant long-term
capital requirements, it intends to raise funds through the sale of debt or
equity securities when conditions are favorable, even if the Company does not
have an immediate need for additional capital at such time. There can be no
assurance that additional financing will be available or that, if available, it
would be available on favorable terms. In addition, the sale of additional debt
or equity securities could result in dilution to the Company's stockholders.
If OP-1 is not approved for commercial sale in the United States beyond its
limited approval under the Humanitarian Device Exemption provision and the
Company does not receive significant royalties from Stryker for product sales
and/or if substantial additional funding is not available, the Company's
business will be materially and adversely affected.
NEW ACCOUNTING STANDARDS
In June 1998, the Financial Accounting Standards Board (FASB) released SFAS No.
133, Accounting for Derivative Instruments and Hedging Activities. SFAS No. 133
establishes standards for reporting and accounting for derivative instruments,
including derivative instruments embedded in other contracts, and for hedging
activities. It requires an entity to recognize all derivatives as either assets
or liabilities in its balance sheet and measure those instruments at fair value.
Pursuant to SFAS No. 137, Accounting for Derivative Instruments and Hedging
Activities - Deferral of the Effective Date of FASB Statement No. 133, SFAS
No.133 is effective for all quarters of fiscal years beginning after June 15,
2000. The Company adopted this new accounting standard in the first quarter of
fiscal 2001. The adoption of SFAS No. 133 did not have any impact on the
Company's reported consolidated financial statements.
On June 30, 2001, the FASB issued SFAS No. 141, Accounting for Business
Combinations and SFAS No. 142, Accounting for Goodwill and Other Intangible
Assets. SFAS No. 141 requires that all business combinations initiated after
June 30, 2001 be accounted for under the purchase method. Upon adoption of SFAS
142, goodwill will no longer be subject to amortization over its estimated
useful life. Rather, goodwill and assembled workforce will be subject to at
least an annual assessment of impairment by applying a fair-value based test.
Upon adoption of SFAS 142 on January 1, 2002, the Company will cease
amortization of its existing goodwill and assembled workforce thereby reducing
its operating expenses by approximately $11,500,000 annually. The Company has
not yet assessed the impairment, if any, that would be recognized utilizing a
fair-value based goodwill impairment test.
18
CAUTIONARY FACTORS WITH RESPECT TO FORWARD-LOOKING STATEMENTS
Readers are cautioned that certain statements contained in this Management's
Discussion and Analysis of Financial Condition and Results of Operations that
are not related to historical results are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995. Statements
that are predictive, that depend upon or refer to future events or conditions,
or that include words such as "expects," "anticipates," "intends," "plans,"
"believes," "estimates," "hopes," and similar expressions constitute forward-
looking statements. In addition, any statements concerning future financial
performance (including future revenues, cashflows, earnings, funding or growth
rates), ongoing business strategies or prospects, and possible future Company
actions are also forward-looking statements.
Forward-looking statements are based on current expectations, projections and
assumptions regarding future events that may not prove to be accurate. Actual
results may differ materially from those projected or implied in the forward-
looking statements. Factors that could cause or contribute to such differences
include, but are not limited to, dependence on significant collaborative
partners, failure or delay in obtaining necessary regulatory approvals, the
ability to protect the Company's intellectual property rights, the ability to
manage future indebtedness and liquidity and the ability to compete effectively.
For a discussion of these and certain other factors, please refer to Item 1.
"Business-Risk Factors" contained in the Company's Post Effective Amendment No.
1 on Form S-3 to the Registration Statement on Form S-1 (File No. 333-50906)
filed with the Securities and Exchange Commission on August 10, 2001. Please
also refer to the Company's other filings with the Securities and Exchange
Commission.
19
ITEM 3. QUANTATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Company invests cash balances in excess of operating requirements in short-
term marketable securities, generally corporate debt and government securities
with an average maturity of less than one year. All marketable securities are
considered available for sale. At September 30, 2001, the fair market value of
these securities amounted to approximately $12,785,000 with net unrealized gains
of approximately $43,000 included as a component of stockholders' equity.
Because of the quality of the investment portfolio and the short-term nature of
the marketable securities, the Company does not believe that interest rate
fluctuations would impair the principal amount of the securities. The Company's
investments are investment grade securities and deposits are with investment
grade financial institutions. The Company believes that the realization of
losses due to changes in credit spreads is unlikely as the Company expects to
hold the debt to maturity.
As of September 30, 2001, in addition to the marketable securities discussed
above, the Company held 53,571 shares of the common stock of Exelixis, Inc.
which as of that date had a fair market value of approximately $614,000. These
shares are restricted under the terms of an agreement between the Company and
Exelixis and will not be available for sale until the one-year holding period
has been satisfied on March 13, 2002. The value of these shares could fluctuate
based on the price of Exelixis common stock and market conditions.
As of September 30, 2001, the Company held assets denominated in EUROS on its
balance sheet totaling $4,483,000. The underlying assets are expected to a have
holding period in excess of one year. The value of these assets could fluctuate
based on changes in the exchange rate between the dollar and EURO. The Company
has not entered into any hedging agreements relating to this risk.
As of September 30, 2001, the Company had approximately $3,501,000 outstanding
under fixed-rate capital leases and term notes which are not subject to
fluctuations in interest rates and approximately $4,052,000 outstanding under a
term loan agreement with an adjustable rate equal to prime or the current LIBOR
rate plus two and one-half basis points, whichever is lower.
20
PART II - OTHER INFORMATION
Item 2. CHANGES IN SECURITIES AND USE OF PROCEEDS
On July 18, 2001, the Company issued 1,000 shares of a newly created Series A
Convertible Exchangeable Preferred Stock ("Preferred Stock"), 546,000 shares of
the Company's common stock (the "Common Stock") and a warrant to purchase 50,000
shares of the Company's common stock (the "Warrant") to Elan International
Services, Ltd in a private placement as a part of the formation of its joint
venture with Elan. The Preferred Stock, Common Stock and Warrant were issued in
consideration of $16,015,000. The securities were offered under the exemption
from registration set forth in Section 4 (2) of the U.S Securities Act of 1933,
as amended. The Preferred Stock is entitled to a 6% annual dividend, payable by
the issuance of additional shares of Preferred Stock. In addition, the
Preferred Stock is entitled to a dividend preference with respect to any
dividends declared or distributions payable to holders of the Company's common
stock, and to a liquidation preference with respect to transactions involving
the liquidation, winding up or sale of the Company. The exercise price of the
warrant is $10.46. The Warrant expires on July 18, 2006.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
(a) Exhibits.
The exhibits listed in the Exhibit Index immediately
preceding such exhibits are filed as part of and are
included in this report.
(b) Reports on Form 8-K.
(i) On July 2, 2001, the Company filed a Current Report on Form 8-
K to report under Item 5 (Other Events) that the Company had
entered into a business collaboration with Micromet, AG. No
financial statements were required to be filed with this
Report.
(ii) On July 5, 2001, the Company filed a Current Report on Form 8-
K to report under Item 5 (Other Events) that the Company had
entered into a joint venture with Elan International Services.
No financial statements were required to be filed with this
Report.
(iii) On September 21, 2001, the Company filed a Current Report on
Form 8-K to report under Item 5 (Other Events) a change in the
Company's management structure. No financial statements were
required to be filed with this Report.
21
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the Registrant has duly caused this Quarterly Report on Form 10-Q to be signed
on its behalf by the undersigned, thereunto duly authorized.
CURIS, INC.
Date: November 13, 2001 By: /s/ George A. Eldridge
- ------------------------ ------------------------------
Vice President, Finance and
Chief Financial Officer
22
Exhibit Index
Number Description
- ------ -----------
3.1 Restated Certificate of Incorporation of Curis, Inc. (previously filed
as an exhibit to the Joint Proxy Statement Prospectus on Form S-4 of
Curis, Inc. (filed on June 19, 2000 (File No. 333-32446)) and
incorporated herein by reference).
3.2 Certificate of Designations of Curis, Inc. (previously filed as an
exhibit to the Post-Effective Amendment No. 1 on Form S-3 to the
Registration Statement on Form S-1 of Curis, Inc. (filed August 10,
2001 (File No. 333-50906)) and incorporated herein by reference).
3.3 Amended and Restated By-laws of Curis, Inc. (previously filed as an
exhibit to the Registration Statement on Form S-1 of Curis, Inc. (filed
on December 19, 2000 (File No. 333-50906)) and incorporated herein by
reference).
4.1 Registration Rights Agreement, dated as of July, 18 2001, among Curis,
Inc., Elan International Services, Ltd. and Elan Pharma International
Limited (previously filed as an exhibit to the Quarterly Report on Form
10-Q of Curis, Inc. (filed on August 14, 2001) and incorporated herein
by reference).
4.2 Convertible Promissory Note dated July 18, 2001 made by Curis, Inc. in
favor of Elan Pharma International Ltd.
10.1 Securities Purchase Agreement, dated as of July 18, 2001, among Curis,
Inc., Elan International Services, Ltd. and Elan Pharma International
Limited (previously filed as an exhibit to the Quarterly Report on
Form 10-Q of Curis, Inc. (filed on August 14, 2001) and incorporated
herein by reference).
10.2 Secured Promissory Note dated August 3, 2003 made by Doros Platika in
favor of Curis, Inc.
10.3 Employment Agreement dated September 20, 2001 between Curis, Inc. and
Daniel R. Passeri.
23